rgi-2001
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2019 (NCT04014790)
Timeline
Indications
Studied for
- Graft vs Host Disease · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 1
- Hodgkin Disease · Phase 1
- Leukemia, Lymphoid · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Antigen-presenting glycoprotein CD1dINHIBITOR
CD1D inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04473911 | Phase 1 | Aug 14, 2020 | Harvard University, Regimmune Inc. |
| NCT04014790 | Phase 2 | Aug 31, 2019 | Harvard University, Regimmune Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 1 | 2 | 2019 |
| Regimmune Inc. | For profit | 2 | 1 | 2 | 2019 |
2 organizations
Page 1 / 1